WO2012089643A1 - Dusp22 à titre de marqueur pronostique dans le cancer du sein humain - Google Patents

Dusp22 à titre de marqueur pronostique dans le cancer du sein humain Download PDF

Info

Publication number
WO2012089643A1
WO2012089643A1 PCT/EP2011/073905 EP2011073905W WO2012089643A1 WO 2012089643 A1 WO2012089643 A1 WO 2012089643A1 EP 2011073905 W EP2011073905 W EP 2011073905W WO 2012089643 A1 WO2012089643 A1 WO 2012089643A1
Authority
WO
WIPO (PCT)
Prior art keywords
copy number
dusp22
breast cancer
gene
expression level
Prior art date
Application number
PCT/EP2011/073905
Other languages
English (en)
Inventor
Xavier Sastre
Jérôme Couturier
Original Assignee
Institut Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Curie filed Critical Institut Curie
Publication of WO2012089643A1 publication Critical patent/WO2012089643A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • DUSP22 as a prognostic marker in human breast cancer
  • the present invention relates to the field of medicine, in particular of oncology. It provides a new prognostic marker in human breast cancer. BACKGROUND OF THE INVENTION
  • Cancer occurs when cell division gets out of control and results from impairment of a DNA repair pathway, the transformation of a normal gene into an oncogene or the malfunction of a tumor supressor gene. Many different forms of cancer exist. While different forms of cancer have different properties, one factor which many cancers share is the ability to metastasize. Distant metastasis of all malignant tumors remains the primary cause of death in patients with the disease.
  • Breast cancer is the most common cancer in women in Western countries. While germ line mutations in BRCA 1 or BRCA2 genes predi spose women with the mutations to breast cancer, only about 5-10% of breast cancers are associated with these breast cancer susceptibility genes. Currently employed clinical indicators of breast cancer prognosi s are not accurate in identifyi ng patients likely to have a favorable outcome. As a result, many more patients are subjected to adjuvant chemotherapy than i ll benefit from such treatment. Due to the increased morbidity and mortality if breast cancer is not detected early in its progression, considerable effort has been devoted to early detection of breast tumor development and it remains a need in the art for better and more speci fic clinical predictors of breast cancer prognosis.
  • the therapeutic care of the patients having cancer is primarily based on surgery, radiotherapy and chemotherapy and the practitioner has to choose the most adapted therapeutic strategy for the patient. In the majority of the cases, the choice of the therapeutic protocol is based on the anatomo-pathological and clinical data.
  • the methods to determine breast cancer prognosis and select patients for adjuvant therapy is mainly established based upon parameters such as tumor size, tumor grade, the age of the patient, and lymph node metastasis. Accurate prognosis or determination of distant metastasis- ree survival in breast cancer patients would permit selective administration of adjuvant therapy, with women having poorer prognosis being given the most aggressive treatment. However, it is very difficult to predict which localized tumor will eventuate in distant metastasis.
  • prognostic markers that can accurately distinguish tumors associated with good prognosis including low probability of metastasis, late disease progression, decreased disease recurrence or increased patient survival, from the others.
  • the practitioner can predict the patient's prognosis and can effectively target the individuals who would most likely benefit from therapy or who need a more intensive monitoring.
  • the inventors demonstrate that a high copy number of 6p25 chromosome region or copy number and/or expression level of a gene included in this region, in particular DUSP22 gene, in a subject having a breast cancer is correlated with a good prognosis including late disease progression, decreased metastasis formation, decreased disease recurrence and/or increased patient survival.
  • the present invention concerns a method for predicting the clinical outcome of a subject affected with breast cancer, wherein the method comprises the step of determining the copy number of the 6p25 chromosome region or the copy number and/or expression level of a gene included in said region in a sample from said subject, a high copy number of said 6p25 chromosome region or of said gene thereof and/or a high expression level of said gene being indicative of a good prognosis.
  • a good prognosis is an increased patient survival and/or a late disease progression and/or a decreased disease recurrence and/or a decreased metastasis formation.
  • the present invention concerns a method for selecting a subject affected with breast cancer for a therapy, preferably an adjuvant therapy, or determining whether a subject affected with breast cancer is susceptible to benefit from a therapy, preferably an adjuvant therapy, wherein the method comprises the step of determining the copy number of the 6p25 chromosome region or the copy number and/or expression level of a gene included in said region in a sample from said subject, a low copy number of said 6p25 chromosome region or of said gene thereof and/or a low expression level of said gene indicating that a therapy, preferably an adjuvant therapy, is required.
  • the gene included in 6p25 chromosome region is DUSP22.
  • the copy number of the 6p25 chromosome region or of a gene included in this region, preferably DUSP22 gene is determined by quantitative or semiquantitative PCR, or by real time quantitative or semi-quantitative PCR, in situ hybridization (such as fluorescent in situ hybridization (FISH)), Southern blotting, array-based methods and/or comparative genomic hybridization (CGH). More preferably, detection is performed by comparative genomic hybridization (CGH).
  • the expression level of a gene included in 6p25 chromosome region is determined by measuring the quantity of protein or mRNA encoded by said gene, preferably DUSP22 protein or DUSP22 mRNA, more preferably DUSP22 protein.
  • the quantity of protein may be measured by immunohistochemistry, semi-quantitative Western-blot or by protein or antibody arrays, and the quantity of mRNA may be measured by quantitative or semi-quantitative RT-PCR, or by real time quantitative or semi-quantitative RT-PCR, or by Northern blot or by transcriptome approaches.
  • the sample is a breast cancer sample.
  • the reference copy number and/or the reference expression level is the copy number and /or expression level of in a normal sample or frequently present in a control group.
  • the breast cancer is an early stage breast cancer without local or systemic invasion, preferably a small-size breast cancer.
  • Figure 1 Proportion of tumors exhibiting a genomic gain at the 6p25.3 locus according to the metastatic status in the bone marrow (MO) and the axillary sentinel node (GS). Metastatic status was classified as positive (1) (presence of metastatic cells) or negative (0) (no metastatic cells). Numbers in histogram bars correspond to the number of cases with a genomic gain reported to the total number of cases in each class.
  • FIG. 2 SNP6 analysis of six cases of invasive breast carcinoma (T1-T6) with that of the corresponding non tumor tissues (N1-N6) for each case.
  • the copy number variation of the DNA observed at the 6p25 locus in tumor tissues either as gains (dotted lines) (T2, T3, T6) or losses (full lines) (Tl, T5) is also observed in non tumor tissues (gains in N2, N3, N6 and losses in Nl, N5). This indicates that the variation observed corresponds to a copy number polymorphism.
  • a very slight increase in tumor T4 is not clearly detected in the corresponding normal tissue (N4).
  • the locus of the DUSP22 gene, indicated at the top, is located at the medium part of the region.
  • Figure 3 Invasive ductal carcinoma of the breast: significant expression level of DUSP22 in the nucleus of the tumor cells.
  • Genomeome variability in the human genome takes many forms, ranging from large, microscopically visible chromosome anomalies to single-nucleotide changes.
  • the genomic sequence within populations is not identical when individuals are compared. Rather, the genome exhibits sequence variability between individuals at many locations in the genome. Such variations in sequence are commonly referred to as polymorphisms, and there are many such polymorphism sites within each genome.
  • Beside single nucleotide polymorphisms (SNPs) many other types of sequence variants are found in the human genome, including mini- and microsatellites, and insertions, deletions, inversions, duplications and complex multi-site variants collectively termed copy number variations (CNVs) or copy number polymorphisms (CNPs).
  • CNVs are receiving increased attention. These large-scale polymorphisms (typically 1 kb or larger) account for polymorphic variation affecting a substantial proportion of the assembled human genome; known CNVs covery over 15 percent of the human genome sequence (Estivill et al, 2007). Most of these polymorphisms are however very rare, and, on average, affect only a fraction of the genomic sequence of each individual. CNVs are known to affect gene expression, phenotypic variation and adaptation by disrupting gene dosage, and are also known to cause disease (microdeletion and microduplication disorders) and confer risk of common complex diseases, including HIV-I infection and glomerulonephritis (Redon et al, 2006).
  • CGH comparative genomic hybridization
  • genotyping including use of genotyping arrays, as described by Carter (Nature 2007).
  • the Database of Genomic Variants http://projects.tcag.ca/variation/) contains updated information about the location, type and size of described CNVs. The database currently contains data for over 15,000 CNVs.
  • Recurrent chromosomal alterations are a hallmark of cancer cells and represent critical events in tumor development.
  • oncogene activation through increased gene copy number resulting in overexpression contributes to the malignant transformation of various human solid cancers, including breast cancer (Collins et al, 2001).
  • major recurrent ampl icons include 17q 12 (ERBB2/HER-2), 8q24 (MYC), 11 q 13 (CCNDJ), 20q l 3, and 8p l 1 - 12 (Ethier et al, 2003).
  • Inventors herein demonstrate that the copy number and/or expression level of a gene included in 6p25 chromosome region, in particular DUSP22 gene, are correlated with good prognosis.
  • Copy number and/or expression level of this gene included in 6p25 chromosome region thus constitutes a marker for the prognosis of breast cancer.
  • DUSP22 (or Dual specificity phosphatase 22) is also designated as LMW-DSP2 (low molecular weight dual specificity phosphatase 2); JKAP (INK pathway associated phosphatase); JSP1 (JNK-stimulatory phosphatase 1); MKP-x (mitogen-activated protein kinase phosphatase x); VHX (VHR related MKPX) or FLJ35864.
  • DUSP22 is a Dual specificity phosphatase/MAPK-phosphatase known to regulate MAPK-mediated signaling pathways. More specifically, DUSP22 have been shown to positively regulate INK or p38 MAPK pathways.
  • DUSP22 contained a single DSP (Dual Specific Phosphatase) catalytic domain but lacked the cdc25 homology domain, which is conserved in most known MKPs.
  • DUSP22 contains a Protein Tyrosine Phosphatase (PTP) signature motif HCxxGxxR and is expressed in various tissues and cells.
  • PTP Protein Tyrosine Phosphatase
  • DUSP22 has been shown to regulate T-cell antigen receptor signaling through ERK2 (Alonso et al, 2002). Sekine and al have also demonstrated that DUSP22 is a negative regulator of interleukin-6 (IL-6)/leukemia inhibitory factor (LIF)-mediated signaling by dephosphorylating STAT-3 (Sekine et al, 2006). Lewintre et al validate in 2009 a set of putative prognostic markers of B cell chronic lymphocytic leukemia (CLL) which are differentially expressed genes according to IgV H gene status, i.e unmutated or mutated. DUSP22 is found overexpressed in CLL cells in this study. Definitions
  • DUSP22 refers to the Dual specificity phosphatase 22. Accession number corresponding to the human DUSP22 gene in Genbank is M 020185, and accession number corresponding to the human DUSP22 protein is P 064570. This protein is encoded by the gene DUSP22 (GenelD: 56940).
  • cancer refers to the presence of cells possessing characteristics typical of cancer-causing cells, such as uncontrolled proliferation, immortality, metastatic potential, rapid growth and proliferation rate, and certain characteristic morphological features.
  • the cancer is a breast cancer, more preferably a breast cancer in an early stage without local or systemic invasion, still more preferably a small-size breast cancer.
  • CNV copy number of a chromosome region or of a gene
  • a CNV can be simple in structure, such as tandem duplication, or may involve complex gains or losses of homologous sequences at multiple sites in the genome.
  • the high or low copy number of a chromosome region or of a gene is, respectively, more or less frequently present in an individual affected for breast cancer, compared to the frequency of its presence in a comparison group (control).
  • the control group may in one embodiment be a population sample, i.e. a random sample from the general population.
  • the control group is represented by a group of individuals who are breast cancer-free. Such breast cancer -free controls are those that have not been diagnosed with the breast cancer.
  • the breast cancer -free control group is characterized by the absence of one or more breast cancer -poor prognosis markers or characterized by the presence of one or more breast cancer -good prognosis markers.
  • treatment refers to any act intended to ameliorate the health status of patients such as therapy, prevention, prophylaxis and retardation of the disease.
  • such term refers to the amelioration or eradication of a disease or symptoms associated with a disease.
  • this term refers to minimizing the spread or worsening of the disease resulting from the administration of one or more therapeutic agents to a subject with such a disease.
  • therapy refers to any type of treatment of cancer (i.e., antitumoral therapy), including an adjuvant therapy and a neoadjuvant therapy.
  • Therapy comprises radiotherapy and therapies, preferably systemic therapies such as hormone therapy, chemotherapy, immunotherapy and monoclonal antibody therapy.
  • adjuvant therapy refers to any type of treatment of cancer given as additional treatment, usually after surgical resection of the primary tumor, in a patient affected with a cancer that is at risk of metastasizing and/or likely to recur.
  • adjuvant therapies comprise radiotherapy and therapy, preferably systemic therapy, such as hormone therapy, chemotherapy, immunotherapy and monoclonal antibody therapy.
  • hormone therapy refers to a cancer treatment having for purpose to block, add or remove hormones.
  • hormone therapy is given to block estrogen and a non-exhaustive list commonly used drugs includes: Tamoxifen, Toremifene, Anastrozole, Exemestane, Letrozole, Goserelin/Leuprolide, Megestrol acetate, and Fluoxymesterone.
  • chemotherapeutic treatment refers to a cancer therapeutic treatment using chemical or biochemical substances, in particular using one or several antineoplastic agents.
  • radiotherapeutic treatment or “radiotherapy” is a term commonly used in the art to refer to multiple types of radiation therapy including internal and external radiation therapies or radioimmunotherapy, and the use of various types of radiations including X-rays, gamma rays, alpha particles, beta particles, photons, electrons, neutrons, radioisotopes, and other forms of ionizing radiations.
  • the term “good prognosis” refers to an increased patient survival and/or a late disease progression and/or a decreased disease recurrence and/or a decreased metastasis formation.
  • the term “poor prognosis” indicates a decreased patient survival and/or an early disease progression and/or an increase disease recurrence and/or an increase metastasis formation.
  • the term “subject” or “patient” refers to an animal, preferably to a mammal, even more preferably to a human, including adult and child.
  • the term “subject” can also refer to non-human animals, in particular mammals such as dogs, cats, horses, cows, pigs, sheeps and non-human primates, among others, that are in need of treatment.
  • sample means any sample containing cells derived from a subject, preferably a sample which nucleic acids and/or proteins.
  • samples include fluids such as blood, plasma, saliva, and urine as well as biopsies, organs, tissues or cell samples.
  • the sample may be treated prior to its use.
  • breast cancer sample refers to any sample containing breast tumoral cells derived from a patient, preferably a sample which contains nucleic acids and/or proteins.
  • the sample contains only tumoral cells.
  • normal sample refers to any sample which does not contain any tumoral cells.
  • the term "reference copy number” refers to copy number of a chromosome region or of a gene thereof which is frequently present in a control group or to copy number of chromosome region or gene thereof in a normal sample.
  • the normal sample is a non-tumoral sample.
  • the normal sample may be obtained from the subject affected with the breast cancer or from another subject, preferably a normal or healthy subject, i.e. a subject who does not suffer from a breast cancer.
  • the copy number of a chromosome region or of a gene of a control group e.g.
  • a group of individuals characterized by the absence of breast cancer or by the presence of breast cancer with good prognosis can be compared to copy number of a chromosome region or of a gene presents in an individual characterized by the presence of breast cancer with poor prognosis.
  • the reference copy number may be established based on retrospective studies, in particular from samples thereof.
  • the term "reference expression level” refers to expression level of a gene which is frequently present in a control group or to expression level of the gene in a normal sample.
  • the normal sample is a non-tumoral sample.
  • the normal sample may be obtained from the subject affected with the cancer or from another subject, preferably a normal or healthy subject, i.e. a subject who does not suffer from a breast cancer.
  • the expression level of a chromosome region or of a gene of a control group e.g. a group of individuals characterized by the absence of breast cancer or by the presence of breast cancer with good prognosis, can be compared to expression level of a gene presents in an individual characterized by the presence of breast cancer with poor prognosis.
  • the reference copy number may be established based on retrospective studies, in particular from samples thereof.
  • the methods of the invention as disclosed below may be in vivo, ex vivo or in vitro methods, preferably in vitro methods.
  • an increased expression level of DUSP22 has been monitored in lymphocytes derived from radiation-exposed individuals (Fachin et al, 2009).
  • IR ionizing radiation
  • the present invention concerns a method for predicting clinical outcome of a subject affected with a breast cancer, wherein the method comprises the step of determining copy number of 6p25 chromosome region, in particular 6p25.3, or copy number and/or expression level of a gene included in this region, in particular DUSP22, in a breast cancer sample from said subject, a high copy number of 6p25 chromosome region or a high copy number and/or expression level of a gene thereof being indicative of a good prognosis.
  • the present invention concerns a method for predicting clinical outcome of a subject affected with a breast cancer, wherein the method comprises the step of determining copy number of 6p25 chromosome region, in particular 6p25.3, or copy number and/or expression level of a gene included in this region, in particular DUSP22, in a breast cancer sample from said subject, a low copy number of 6p25 chromosome region or a low copy number and/or expression level of a gene thereof being indicative of a poor prognosis.
  • the gene included in 6p25 chromosome region is DUSP22.
  • the method further comprises the step of providing a sample from the subject.
  • the sample is a breast cancer sample. This sample may be provided from a biopsy or from a chirurgical resection.
  • the sample is a blood or serum sample from the subject. Indeed, it is hypothesized that the copy number variation is constitutional and not acquired. Therefore, a blood or serum sample may contain the same information than a breast cancer sample.
  • the copy number of the 6p25 chromosome region or of a gene included in this region is determined by quantitative or semi-quantitative PCR, or by real time quantitative or semi- quantitative PCR, in situ hybridization (such as fluorescent in situ hybridization (FISH)), Southern blotting, array-based methods and/or comparative genomic hybridization (CGH).
  • the DNA may be genomic fragmented (e.g., sonicated, nebulized, restriction enzyme digested, sheared), or whole (e.g., not intentionally fragmented).
  • a microarray assay is a nucleic acid assay for CGH for identification of insertions and/or deletions in a genome wherein both a reference genomic DNA sample and a test genomic DNA sample are compared.
  • the expression level of a gene included in 6p25 chromosome region can be determined from a sample by a variety of techniques.
  • the expression level of a gene included in 6p25 chromosome region is determined by measuring the quantity of protein or mRNA encoded by said gene, preferably DUSP22 protein or DUSP22 mRNA, more preferably DUSP22 protein.
  • the expression level of a gene included in 6p25 chromosome region, preferably DUSP22 gene is determined by measuring the quantity of protein, preferably DUSP22 protein.
  • the quantity of protein may be measured by any methods known by the skilled person. Usually, these methods comprise contacting the sample with a binding partner capable of selectively interacting with the protein present in the sample.
  • the binding partner is generally a polyclonal or monoclonal antibody, preferably monoclonal. Polyclonal and monoclonal antibodies anti-DUSP22 are commercially available.
  • Examples of these marketed antibodies are the rabbit polyclonal anti-DUSP22 from GenWay Biotech (Ref N° 18-461-10260), the rabbit polyclonal anti-human DUSP22 from ProteinTech Group (Ref N° 51005-2- AP), and the mouse polyclonal anti-DUSP22 from Sigma- Aldrich (Ref N° SAB 1401777).
  • the other antibodies used in the different methods to quantify the DUSP22 protein are well known by the skilled person and are commercially available.
  • the quantity of protein may be measured by semi-quantitative Western blots, enzyme-labeled and mediated immunoassays, such as ELISAs, biotin/avidin type assays, radioimmunoassay, Immunoelectrophoresis or immunoprecipitation or by protein or antibody arrays.
  • the protein expression level may be assessed by immunohistochemistry on a tissue section of the sample (e.g. frozen or formalin-fixed paraffin embedded material).
  • the reactions generally include revealing labels such as fluorescent, chemiluminescent, radioactive, enzymatic labels or dye molecules, or other methods for detecting the formation of a complex between the antigen and the antibody or antibodies reacted therewith.
  • the quantity of protein is measured by immunohistochemistry or semi-quantitative western-blot.
  • a gene included in 6p25 chromosome region is determined by measuring the quantity of mRNA, preferably DUSP22 mRNA.
  • Methods for determining the quantity of mRNA are well known in the art.
  • the nucleic acid contained in the sample e.g., cell or tissue prepared from the patient
  • the extracted mRNA is then detected by hybridization (e. g., Northern blot analysis) and/or amplification (e.g., RT-PCR).
  • hybridization e. g., Northern blot analysis
  • amplification e.g., RT-PCR
  • Real-time quantitative or semi-quantitative RT-PCR is particularly advantageous.
  • primer pairs were designed in order to overlap an intron, so as to distinguish cDNA amplification from putative genomic contamination.
  • An example of primer pair which may be used in this method is presented in the experimental section and is constituted by the primers couple Hs00169616_ml or Hs00414885_ml commercialized by TaqManR Gene Expression Assays Applied Biosystems. Other primers may be easily designed by the skilled person.
  • Other methods of Amplification include ligase chain reaction (LCR), transcription-mediated amplification (TMA), strand displacement amplification (SDA) and nucleic acid sequence based amplification (NASBA).
  • LCR ligase chain reaction
  • TMA transcription-mediated amplification
  • SDA strand displacement amplification
  • NASBA nucleic acid sequence based amplification
  • the quantity of mRNA is measured by quantitative or semi-quantitative RT-PCR or by real-time quantitative or semi
  • the method further comprises the step of comparing the copy number of 6p25 chromosome region or copy number and/or expression level of a gene included in this region to a reference copy number and/or to a reference expression level.
  • the reference copy number is the copy number of a chromosome region or of a gene thereof which is frequently present in a control group or to copy number of chromosome region or gene thereof in a normal sample.
  • the normal sample is a non-tumoral sample.
  • the copy number of a chromosome region or of a gene of a control group e.g. a group of individuals characterized by breast cancer or by the presence of breast cancer with good prognosis, can be compared to copy number of a chromosome region or of a gene presents in an individual characterized by the presence of breast cancer with poor prognosis.
  • the reference copy number may be established based on retrospective studies, in particular from samples thereof.
  • the reference expression level is expression level of the gene in a normal sample.
  • the normal sample is a non-tumoral sample, preferably from the same tissue than the cancer sample.
  • the normal sample may be obtained from the subject affected with the cancer or from another subject, preferably a normal or healthy subject, i.e. a subject who does not suffer from a cancer.
  • Expression levels obtained from cancer and normal samples may be normalized by using expression levels of proteins which are known to have stable expression such as RPLPO (acidic ribosomal phosphoprotein PO), TBP (TATA box binding protein), GAPDH (glyceraldehyde 3 -phosphate dehydrogenase) or ⁇ -actin.
  • the reference expression level is the expression level of a gene having a stable expression in different cancer samples.
  • genes include for example, RPLPO, TBP, GAPDH or ⁇ -actin.
  • the reference expression level is the expression level of the TBP gene.
  • the quantity of mRNA preferably DUSP22 mRNA
  • the quantity of mRNA is normalized according to the quantity of TBP mRNA.
  • the quantity of TBP mRNA is used as reference quantity (i.e. 100%).
  • the quantity of mRNA, preferably DUSP22 mRNA is expressed as a relative quantity with respect to the quantity of TBP mRNA.
  • the reference expression level is the expression level of a gene included in 6p25 chromosome region (i.e., DUSP22) in a normal sample
  • the expression level of a gene included in 6p25 chromosome region, in the breast cancer sample is considered as high if, after normalization, the level is at least 2-fold higher than the expression level in the normal sample.
  • the expression level of a gene included in 6p25 chromosome region, preferably DUSP22 gene, in the breast cancer sample is considered as high if the level is at least 3 -fold higher, or 5 or 10-fold higher, than the expression level in the normal sample.
  • the present method further comprises assessing at least one another cancer or prognosis marker such as tumor grade, hormone receptor status, mitotic index, tumor size, HJURP expression level or expression of proliferation markers such as Ki67, MCM2, CAF-1 p60, CAF-1 pi 50, HPlalpha and ASFlb.
  • cancer or prognosis marker such as tumor grade, hormone receptor status, mitotic index, tumor size, HJURP expression level or expression of proliferation markers such as Ki67, MCM2, CAF-1 p60, CAF-1 pi 50, HPlalpha and ASFlb.
  • proliferation markers such as Ki67, MCM2, CAF-1 p60, CAF-1 pi 50, HPlalpha and ASFlb.
  • the tumor grade may be determined according the Elston & Ellis method (Elston & Ellis, 2002), the hormone receptor status (estrogen and progesterone) may be determined at the protein or at the mRNA level, the mitotic index may be determined by counting mitotic cells in ten microscopic fields of a representative tissue section and the tumor size can be detected by imaging techniques (e.g. mammography), by palpation or after surgery in the excised tissue.
  • Expression of Ki67 and CAF-1 can be assessed at the protein level or at the mRNA level. High grade, high mitotic index, large size and/or high Ki67 or CAF-1 expression are indicative for a worse prognosis.
  • the HJURP expression level may be assessed as described in Hu et al., 2010. High HJURP expression is associated with poor clinical outcomes.
  • HPlalpha and ASFlb have also been identified as prognosis marker in breast cancer (EP 10 164 424.3 and WO 2010/122137, respectively).
  • the present invention concerns a method for selecting a subject affected with a breast cancer for a therapy, preferably an adjuvant therapy, or determining whether a subject affected with a breast cancer is susceptible to benefit from a therapy, preferably an adjuvant therapy, wherein the method comprises the step of determining copy number of 6p25 chromosome region or copy number and/or expression level of a gene included in this region in a breast cancer sample from said subject, a low copy number of 6p25 chromosome region or a low copy number and/or expression level of a gene thereof indicating that a therapy, preferably an adjuvant therapy, is required.
  • the method further comprises the step of providing a sample or breast cancer sample from the subject.
  • the copy number of 6p25 chromosome region or copy number and/or expression level of a gene included in this region, preferably DUSP22 gene, in the cancer sample is determined as described above, preferably by measuring the quantity of protein or mRNA encoded by said gene, preferably DUSP22 protein or DUSP22 mRNA.
  • the method comprises the step of comparing the copy number of 6p25 chromosome region or copy number and/or expression level of a gene included in this region to a reference copy number and/or to a reference expression level as described above in relation with the method for predicting clinical outcome.
  • the reference copy number is the copy number of a chromosome region or of a gene thereof which is frequently present in a control group or to copy number of chromosome region or gene thereof in a normal sample.
  • the reference expression level may be the expression level of a gene present in a control group or in a normal sample or the expression level of the gene having a stable expression in different cancer samples, such as the TBP gene.
  • the method further comprises the step of determining whether the expression level of gene included in 6p25 chromosome region (i.e., DUSP22) is low compared to said reference expression level.
  • the expression level of the gene included in 6p25 chromosome region (i.e., DUSP22) in the sample is considered as low if, after normalization, the level is of the same order or magnitude than the expression level in the normal sample.
  • a low copy number of 6p25 chromosome region or a low copy number and/or expression level of a gene thereof indicates a decreased patient survival and/or an early disease progression and/or an increase disease recurrence and/or an increase metastasis formation, i.e a poor prognosis.
  • this type of cancer associated with poor prognosis has to be treated with a therapy, preferably an adjuvant therapy, in order to improve the patient's chance for survival.
  • a therapy preferably an adjuvant therapy
  • the type of adjuvant therapy is chosen by the practitioner.
  • this type of cancer also requires a closer monitory of the patient.
  • the present method further comprises assessing at least one another cancer and prognosis marker such as tumor grade, hormone receptor status, mitotic index, tumor size, HJURP expression level or expression of proliferation markers such as Ki67, MCM2, CAF-1 p60, CAF-1 pi 50, HP 1 alpha and ASF lb.
  • prognosis marker such as tumor grade, hormone receptor status, mitotic index, tumor size, HJURP expression level or expression of proliferation markers such as Ki67, MCM2, CAF-1 p60, CAF-1 pi 50, HP 1 alpha and ASF lb.
  • the present invention further concerns the use of a gene included in 6p25 chromosome region as a marker or prognosis marker in breast cancer.
  • the gene included in 6p25 chromosome region i.e., DUSP22
  • the term "prognosis marker” refers to a compound, i.e. a gene included in 6p25 chromosome region or protein thereof (i.e., DUSP22), used to predict or monitor clinical outcome of a subject affected with a breast cancer.
  • the present invention also concerns the use of a the 6p25 chromosome region of a gene included in 6p25 chromosome region (i.e., DUSP22) as a marker for selecting a subject affected with a breast cancer for a therapy, preferably an adjuvant therapy, or determining whether a subject affected with a cancer is susceptible to benefit from for a therapy, preferably an adjuvant therapy.
  • the breast cancer is a human breast cancer.
  • Gene included in 6p25 chromosome region or protein thereof may be used as marker in any one of the methods of the invention as described above.
  • the present invention further concerns a kit
  • kit comprises (i) at least one antibody specific to a protein encoded by a gene included in 6p25 chromosome region (i.e., DUSP22) and, optionally, means for detecting the formation of the complex between said protein and said at least one antibody; and/or
  • At least one probe specific to the genomic DNA, mRNA or cDNA of a gene included in 6p25 chromosome region i.e., DUSP22
  • means for detecting the hybridization of said at least one probe on said genomic DNA, mRNA or cDNA optionally, means for detecting the hybridization of said at least one probe on said genomic DNA, mRNA or cDNA
  • At least one nucleic acid primer pair specific to said genomic DNA, mRNA or cDNA i.e., DUSP22
  • means for amplifying and/or detecting said genomic DNA, mRNA or cDNA optionally, means for amplifying and/or detecting said genomic DNA, mRNA or cDNA ;
  • the first step of treatment was surgery associated with sentinel node (SN) procedure and bone marrow aspiration for the search of occult tumour cells (OTC). Tumours were analysed according to standard histological procedures. Histological analysis included the histological type and grade, the presence of vascular invasion and the Immunohistochemical analysis of estrogen and progesterone receptors and of ERBB2 expression level.
  • All SN were identified separately and fixed in AFA (5% acetic acid, 75% pure ethanol, 18% demineralized water, and 2% formalin). They were cut in two, three, or four parts of equal thickness. Nodes of ⁇ 0.3 cm were not cut. Each lymph node was separately embedded in paraffin. One 3 ⁇ m-thick section was removed from each block and stained with TIES (hematein, eosin, saffron). Cases with all SN free of metastasis (>2 mm) or of micrometastasis (0.2-2 mm) after standard microscopic examination were further analysed using IHC to disclose occult metastasis. Three histologic sections taken at 150- ⁇ intervals were prepared.
  • AFA 5% acetic acid, 75% pure ethanol, 18% demineralized water, and 2% formalin
  • IHC was performed using pan-anti-cytokeratin antibody (Kll, Immunotech, Marseille, France). After rehydration and antigen retrieval in citrate buffer (10 mn, pH 6.1), tissue sections were incubated with the primary monoclonal antibody, for 1 hour, at 1/100 dilution. The revelation of the staining was performed using the Vectastain Elite ABC peroxidase mouse IgG kit (Vector Burlingame, CA) and the diamino-benzidine (DAKO A/S, Glostrup, Denmark), as chromogen. Immunoreactions were done with an automatic immunostainer (TechMate Horizon, LJL Biosystems Inc.).
  • BM sampling, processing and mononuclear cells (MNC) staining have been described previously, along with the sensibility and the specificity of our protocol.
  • MNC mononuclear cells
  • Negative controls stained with anti-FITC IgGl mouse antibody (Sigma Immuno Chemicals), were performed on an equivalent number of cells (i.e. 3 slides, 3 x 10 6 MNC) for each patient. Immune complexes formed by secondary anti-mouse antibody were revealed by the alkaline phosphatase/antialkaline phosphatase reaction, and the slides were counterstained with hematoxylin to study nuclear morphology. Bone marrows were classified according into three categories: absence of detected cytokeratin positive cell (BM-), presence of CK+ cells (OCK+), and presence of CK+ cells with atypical cytology (ITC). Atypical cytology was defined as large cell size (larger than surrounding haematopoietic cells), a high nuclear/cytoplasm ratio for isolated cells, or the presence of clusters of cohesive cells with a large size.
  • the level of expression of the DUSP22 gene was assessed on tumours using immunohistochemistry. Experiments were performed using the rabbit polyclonal anti- DUSP22 antibody (GenWay Biotech San Diego CA; catalogue number 18-461-10260). The antibody was used at the dilution of 1/600, during 20 min, after antigen retrieval procedure at pH9. Experiments were performed in the whole series of 126 cases. Nucleic and cytoplasmic immunolabeling were recorded. The percentage of labelled cells and the staining intensity (+ or ++) were recorded.
  • Results were classified as: 0: non staining; 1 : faint staining (+) in any proportion of the cells; 2 staining (++) in more than 40% of the cells (figure 3). No case with staining intensity ++ in less than 40% of the cells has been observed.
  • genomic status of the 6p25 chromosome region There is a significant association between genomic status of the 6p25 chromosome region and the sub-clinical metastatic status of breast cancer at the time of the diagnosis. 2) The genomic status of this locus is not related to genomic changes in tumor cells but is related to a copy number polymorphism. This polymorphism includes the DUSP22 gene
  • the expression level of the DUSP22 in carcinoma cells is related to the bone marrow status of the patients.
  • VHX VHR-related MKPX
  • VHR VHR-related MKPX

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne un marqueur pronostique dans le cancer du sein humain, un nombre de copies élevé de la région chromosomique 6p25 ou un nombre de copies et/ou un niveau d'expression élevé d'un gène contenu dans cette région étant associé à un bon pronostic. Cette invention concerne également une méthode permettant de sélectionner un sujet affecté par un cancer du sein pour une thérapie.
PCT/EP2011/073905 2010-12-29 2011-12-23 Dusp22 à titre de marqueur pronostique dans le cancer du sein humain WO2012089643A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10306536 2010-12-29
EP10306536.3 2010-12-29

Publications (1)

Publication Number Publication Date
WO2012089643A1 true WO2012089643A1 (fr) 2012-07-05

Family

ID=43823075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/073905 WO2012089643A1 (fr) 2010-12-29 2011-12-23 Dusp22 à titre de marqueur pronostique dans le cancer du sein humain

Country Status (1)

Country Link
WO (1) WO2012089643A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014048942A1 (fr) * 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Sondes pour pten, pik3ca, met et top2a, et procédés d'utilisation de ces sondes
CN111261219A (zh) * 2018-11-14 2020-06-09 立森印迹诊断技术（无锡）有限公司 一种用于检测肝肿瘤良恶性程度的分级模型及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160114A1 (en) * 2004-12-02 2006-07-20 Oncotech, Inc. Reagents and methods for predicting drug resistance
US20090203051A1 (en) * 2006-06-09 2009-08-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
US20090220956A1 (en) * 2005-10-25 2009-09-03 Dimitry Serge Antoine Nuyten Prediction of Local Recurrence of Breast Cancer
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160114A1 (en) * 2004-12-02 2006-07-20 Oncotech, Inc. Reagents and methods for predicting drug resistance
US20090220956A1 (en) * 2005-10-25 2009-09-03 Dimitry Serge Antoine Nuyten Prediction of Local Recurrence of Breast Cancer
US20090203051A1 (en) * 2006-06-09 2009-08-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "PECI gene", 31 December 2010 (2010-12-31), XP002632511, Retrieved from the Internet <URL:http://www.genecards.org/cgi-bin/carddisp.pl?gene=PECI&search=peci> [retrieved on 20110413] *
BERNARD-PIERROT ISABELLE ET AL: "Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer", CANCER RESEARCH, vol. 68, no. 17, September 2008 (2008-09-01), pages 7165 - 7175, XP002632510, ISSN: 0008-5472 *
HYMAN E ET AL: "Impact of DNA amplification on gene expression patterns in breast cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 62, no. 21, 1 November 2002 (2002-11-01), pages 6240 - 6245, XP002317974, ISSN: 0008-5472 *
JENSSEN T-K ET AL: "Associations between gene expressions in breast cancer and patient survival", HUMAN GENETICS, SPRINGER, BERLIN, DE, vol. 111, 23 August 2002 (2002-08-23), pages 411 - 420, XP002963067, ISSN: 0340-6717, DOI: DOI:10.1007/S00439-002-0804-5 *
JU-PI LI ET AL: "JNK Pathway-associated Phosphatase Dephosphorylates Focal Adhesion Kinase and Suppresses Cell Migration", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 285, no. 8, 19 February 2010 (2010-02-19), pages 5472 - 5478, XP007918157, ISSN: 0021-9258, [retrieved on 20091214], DOI: DOI:10.1074/JBC.M109.060186 *
KELLY K HAAGENSON ET AL: "The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 29, no. 1, 29 January 2010 (2010-01-29), pages 143 - 149, XP019787672, ISSN: 1573-7233 *
KOJI AOYAMA ET AL: "Molecular Cloning and Characterization of a Novel Dual Specificity Phosphatase, LMW-DSP2, That Lacks the Cdc25 Homology Domain", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, vol. 276, 20 July 2001 (2001-07-20), pages 27575 - 27583, XP007918156, ISSN: 0021-9258, [retrieved on 20010509], DOI: DOI:10.1074/JBC.M100408200 *
SORLIE T ET AL: "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10869 - 10874, XP002215483, ISSN: 0027-8424, DOI: DOI:10.1073/PNAS.191367098 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014048942A1 (fr) * 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Sondes pour pten, pik3ca, met et top2a, et procédés d'utilisation de ces sondes
CN111261219A (zh) * 2018-11-14 2020-06-09 立森印迹诊断技术（无锡）有限公司 一种用于检测肝肿瘤良恶性程度的分级模型及其应用
CN111261219B (zh) * 2018-11-14 2024-03-22 立森印迹诊断技术（无锡）有限公司 一种用于检测肝肿瘤良恶性程度的分级模型及其应用

Similar Documents

Publication Publication Date Title
Pan et al. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer
Rubin et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
Felsberg et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients
CN102549169B (zh) 子宫内膜癌的标记物
US20090215036A1 (en) Genetic Alterations Useful For The Response Prediction of Malignant Neoplasia to Taxane-Based Medical Treatments
US8999633B2 (en) Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans
Sharma et al. Biomarkers for prostate cancer: present challenges and future opportunities
WO2013003384A1 (fr) Signatures et déterminants associés à la progression du cancer de la prostate et leurs méthodes d&#39;utilisation
Tang et al. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma
EP1989329A2 (fr) Detection et diagnostic de cancers lies au tabagisme
EP3194621B1 (fr) Procédé de prédiction du risque de récurrence du cancer
KR102097859B1 (ko) 위암의 항암제 치료 반응성 예측용 바이오마커 및 이의 용도
Desouki et al. Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach
Gupta et al. BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes
WO2018223867A1 (fr) Marqueur du cancer de la prostate spop et son utilisation dans le guidage d&#39;une thérapie tumorale
US20200172980A1 (en) Prostatic cancer marker, pcdh9, and application thereof
Niini et al. Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone
Lerebours et al. Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer?
Manoharan et al. Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients
Park et al. Transcriptomic analysis of papillary thyroid cancer: a focus on immune-subtyping, oncogenic fusion, and recurrence
Zhao et al. TWIST2: A new candidate tumor suppressor in prostate cancer
WO2014135655A1 (fr) Compositions et méthodes de traitement du cancer de la vessie invasif pour le muscle
KR20150132206A (ko) 예측성 바이오마커에 대한 검정법
Miyaguchi et al. Loss of NKX3-1 as a potential marker for an increased risk of occult lymph node metastasis and poor prognosis in oral squamous cell carcinoma
KR102403807B1 (ko) 항암제 반응성 예측용 바이오마커 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11805042

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11805042

Country of ref document: EP

Kind code of ref document: A1